Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients. MDR
refers to a phenotype whereby a tumor is resistant to a large number of natural
chemotherapeutic drugs. Having prior knowledge of the presence of such resistance would
decrease morbidity from unsuccessful therapy and allow for the selection of individuals who
may benefit from co-administration of MDR inhibiting drugs. The Tc-99m labeled single photon
emitting radiotracers sestamibi and tetrofosmin have shown some predictive value. However,
positron-emitting (PET) radiotracers, which allow for dynamic, quantitative imaging, hold the
promise of more accurate and specific identification of MDR tumors.
Objective:
To obtain human safety data, to demonstrate imaging feasibility with FPAC, to obtain human
biodistribution and to obtain preliminary evidence of breast tumor uptake concordance with
response to therapy.